FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Maintains Buy Opinion On Shares Of Hewlett Packard Enterprise Company

By

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We sharply lift our price target from $28 to $64, based on 16x our FY 27 (Oct.) EPS view, above HPE's three-year average (~9x) on AI tailwinds. We lift our FY 26 EPS view by $1.05 to $3.49 and FY 27's by $1.19 to $4.00. Q2 results (sales +40%, non-GAAP EPS +108%) shattered expectations, along with FY 26's guidance (non-GAAP EPS expected at $3.40, 42% above HPE's prior view). We view the company's initial FY 27 guidance (sales up ~10%, EPS up ~14%) as particularly impressive given ongoing supply constraints, and combined with management's comments on no clear demand pull-in and traditional server units increasing in Q2 despite large ASP increases, we see HPE demonstrating durable pricing power that speaks to the increasing value of its end-to-end offerings (storage, server, networking) following the Juniper acquisition last year. AI demand is also increasingly broadening into enterprise/sovereign spaces, which contributed to the majority of HPE's $5.9B AI systems backlog (+84% Y/Y).

Related Articles

Research

Research Alert: CFRA Keeps Buy Opinion On Shares Of Cme Group Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month target price by $60 to $320, based on a forward P/E of 24.5x our 2027 earnings estimate, a premium to historical averages given an improved margin profile. Our reduced target price reflects rising competition. Previously, we expected CME's valuation multiple to expand alongside solid earnings and revenue growth. However, the CFTC's approval of Bitcoin perpetual futures at Kalshi is likely to pressure valuations for traditional exchange operators as investors fear more approvals are in the pipeline. If regulators extend approval to other asset classes and trading products, traditional exchanges could lose significant market share, especially in retail trading. We believe CME faces moderate risk given its exposure to futures and retail. Other exchanges likely to face pressure include Cboe Global Markets Inc. (CBOE 274 ****), Nasdaq Inc. (NDAQ 88 *****), and Intercontinental Exchange Inc. (ICE 141 ****), noting the last two are less of a concern due to their stronger institutional focus.

$CME
Research

Research Alert: CFRA Lowers Opinion On Shares Of Cboe Global Markets To Buy From Strong Buy

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our reduced opinion reflects rising competition. Previously, we expected CBOE's valuation multiple to continue to expand alongside its strong earnings and revenue growth. However, the CFTC's approval of Bitcoin perpetual futures at Kalshi is likely to pressure valuations for traditional exchange operators as investors fear more approvals are in the pipeline. If regulators extend approval to other asset classes and trading products, traditional exchanges could lose significant market share, especially in retail trading. We believe CBOE faces the greatest risk given its significant, fast-growing retail businesses. CME Group (CME 249 ****), Nasdaq (NDAQ 88 *****), and Intercontinental Exchange (ICE 141 ****) are also likely to face pressure, though less severely due to their stronger institutional focus. We lower our 12-month target price by $85 to $365, based on a forward P/E of 26.6x our 2027 estimate, a premium to the peer average of 19.6x, given less vulnerability to AI disruption and efficiency improvements.

$CBOE
Research

Research Alert: Another Day... Another Berkshire Deal

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Berkshire resumed share buybacks in Q1 2026 with $234M of repurchases after no buybacks in 2025, while maintaining a cash position exceeding $380B at March 31. The company recently completed several major transactions including a $10B investment in Alphabet's $80B equity raise and acquisitions of Taylor Morrison ($8.5B) and Oxychem ($9.7B). We maintain our Hold recommendation on BRK.B shares, believing mixed fundamentals and potential erosion of the "Buffett premium" temper our outlook. Investor reaction to recent M&A has been muted, with most preferring increased share repurchases. We estimate Berkshire has $80B to $100B available for acquisitions and buybacks from its substantial cash reserves. At current levels, shares trade at approximately 22x our 2026 operating EPS estimate, roughly in line with the three-year average forward multiple of 23x. We believe eroding fundamentals and uncertainty surrounding the significant management transition, coupled with adequate valuation, merit caution in the near term.

$BRK.B